Meropenem monotherapy for empiric treatment of febrile neutropenic cancer patients

dc.contributor.authorAyyildiz, O
dc.contributor.authorIskakdogan, A
dc.contributor.authorBolaman, Z
dc.contributor.authorMüftüoglu, E
dc.date.accessioned2024-04-24T17:40:29Z
dc.date.available2024-04-24T17:40:29Z
dc.date.issued2000
dc.departmentDicle Üniversitesien_US
dc.description12th Mediterranean Congress of Chemotherapy -- NOV 11-14, 2000 -- MARRAKECH, MOROCCOen_US
dc.description.abstractEmpirical antibacterial therapy should be administered to all neutropenic cancer patients with fever or clinical evidence of infection even in the absence of fever. A total of fifty cancer patients with 72 neutropenic episodes were enrolled in the study. Twenty-one (29%) episodes had a microbiologically defined infection, 20 (28%) a clinically defined infection and the remaining 31 (43%) had unexplained fever. 72 episodes initially treated with meropenem 1 g i.v. every 8 h. Gram negative pathogens were 11 (52%) predominated over gram positive isolates were 7 (33%). The success rate without adjustment was 29% in gram positive group and 91% in gram negative group. There were no reports of drug-related nausea/ vomiting or seizures. One patient with AML died of gram positive sepsis resistant to treatment. In conclusion,meropenem monotherapy seemed effective and side effects were tolerable for the treatment of febrile neutropenic cancer patients.en_US
dc.identifier.endpage116en_US
dc.identifier.isbn88-323-0211-X
dc.identifier.startpage111en_US
dc.identifier.urihttps://hdl.handle.net/11468/21824
dc.identifier.wosWOS:000172402200017
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherMedimond S R Len_US
dc.relation.ispartof12th Mediterranean Congress of Chemotherapyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleMeropenem monotherapy for empiric treatment of febrile neutropenic cancer patientsen_US
dc.typeConference Objecten_US

Dosyalar